BBNX · Beta Bionics, Inc.
$20.51
+7.05% last session
End-of-day data · close of 2026-10-26
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-9.5
Dividend yield
0.0%
Beta
—
Avg volume
1M
Employees
0K
Daily Change %
7.05%
5 Days Change
6.05%
10 Days Change
25.44%
30 Days Change
-4.65%
60 Days Change
4.01%
Month to Day Change
8.69%
Year to Day Change
-32.69%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BBNX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
Jefferies
Buy$30.00
+46.3% vs priceWells Fargo
Overweight$28.00
+36.5% vs priceBank of America
Neutral$20.00
-2.5% vs priceGoldman Sachs
Buy$19.00
-7.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Jefferies | Initiates | Buy | $0.00 → $30.00 |
| 2026-09-24 | Truist Securities | Maintains | Buy | $23.00 → $28.00 |
| 2026-09-23 | Wells Fargo | Initiates | Overweight | $0.00 → $28.00 |
| 2026-09-15 | Bank of America | Maintains | Neutral | $18.00 → $20.00 |
| 2026-09-15 | Truist Securities | Reiterates | Buy | $22.00 → $23.00 |
| 2026-09-15 | Baird | Maintains | Neutral | $14.00 → $16.00 |
| 2026-09-14 | Leerink Partners | Maintains | Outperform | $24.00 → $27.00 |
| 2026-08-21 | William Blair | Initiates | Market Perform | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 7.0% above the 50-day MA ($19.16).
- bullish: Price vs 200-day MA: Trading 38.5% above the 200-day MA ($14.81).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.28) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($8.86) and high ($31.99).
BBNX Price Chart
Loading chart for BBNX…
Fundamentals
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
More in Medical Devices
ABT
Abbott Laboratories
$181B -14.2% YTD
MDT
Medtronic plc.
$121B 1.2% YTD
SYK
Stryker Corporation
$117B -12.2% YTD
BSX
Boston Scientific Corporation
$66B -52.2% YTD
EW
Edwards Lifesciences Corporatio
$52B 6.2% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.1% YTD
DXCM
DexCom, Inc.
$30B 18.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 1.9% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.